0001193125-22-170180.txt : 20220713 0001193125-22-170180.hdr.sgml : 20220713 20220608160604 ACCESSION NUMBER: 0001193125-22-170180 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220608 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc. CENTRAL INDEX KEY: 0001845337 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832415215 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 395 OYSTER POINT BLVD STE 217 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-1930 BUSINESS PHONE: 206-913-4300 MAIL ADDRESS: STREET 1: 395 OYSTER POINT BLVD STE 217 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-1930 FORMER COMPANY: FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC DATE OF NAME CHANGE: 20210209 CORRESP 1 filename1.htm CORRESP

DAY ONE BIOPHARMACEUTICALS, INC.

395 Oyster Point Blvd., Suite 217

South San Francisco, CA 94080

June 8, 2022

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

 

Attention:

Office of Life Sciences

 

  Re:

Day One Biopharmaceuticals, Inc.

Registration Statement on Form S-3

Filed June 1, 2022

File No. 333-265346

Via EDGAR - Acceleration Request

Requested Date:    June 13, 2022

Requested Time:    9:00 a.m. Eastern Time

Ladies and Gentlemen:

Day One Biopharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.

The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.

Sincerely,
DAY ONE BIOPHARMACEUTICALS, INC.
By:  

/s/ Charles N. York II, M.B.A.

  Charles N. York II, M.B.A.
  Chief Financial Officer

 

cc:

Jeremy Bender, Ph.D., M.B.A., Chief Executive Officer

Charles N. York II, M.B.A., Chief Operating Officer

and Chief Financial Officer

Day One Biopharmaceuticals, Inc.

Robert A. Freedman, Esq.

Julia Forbess, Esq.

Fenwick & West LLP